Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 29, 2024

BUY
$6.63 - $10.69 $3,049 - $4,917
460 Added 3.68%
12,965 $104,000
Q4 2023

Feb 07, 2024

SELL
$3.61 - $7.76 $2,137 - $4,593
-592 Reduced 4.52%
12,505 $85,000
Q3 2023

Nov 02, 2023

BUY
$4.68 - $9.26 $1,413 - $2,796
302 Added 2.36%
13,097 $65,000
Q2 2023

Aug 07, 2023

BUY
$8.5 - $10.38 $12,325 - $15,051
1,450 Added 12.78%
12,795 $116,000
Q1 2023

May 09, 2023

SELL
$7.53 - $10.95 $6,385 - $9,285
-848 Reduced 6.95%
11,345 $107,000
Q4 2022

Feb 09, 2023

BUY
$9.44 - $13.09 $708 - $981
75 Added 0.62%
12,193 $121,000
Q3 2022

Nov 09, 2022

SELL
$8.14 - $12.25 $92,047 - $138,523
-11,308 Reduced 48.27%
12,118 $144,000
Q2 2022

Aug 10, 2022

BUY
$6.99 - $10.0 $85,935 - $122,940
12,294 Added 110.44%
23,426 $192,000
Q1 2022

May 09, 2022

SELL
$7.26 - $10.7 $40,612 - $59,855
-5,594 Reduced 33.44%
11,132 $88,000
Q4 2021

Feb 09, 2022

SELL
$8.8 - $16.0 $205,444 - $373,536
-23,346 Reduced 58.26%
16,726 $157,000
Q3 2021

Nov 09, 2021

SELL
$15.23 - $21.72 $23,545 - $33,579
-1,546 Reduced 3.71%
40,072 $633,000
Q2 2021

Aug 10, 2021

BUY
$17.8 - $23.5 $740,800 - $978,023
41,618 New
41,618 $899,000
Q4 2018

Feb 14, 2019

SELL
$17.09 - $38.25 $233,415 - $522,418
-13,658 Closed
0 $0
Q3 2018

Nov 14, 2018

BUY
$34.05 - $55.9 $13,007 - $21,353
382 Added 2.88%
13,658 $503,000
Q2 2018

Aug 13, 2018

BUY
$36.15 - $52.5 $187,148 - $271,792
5,177 Added 63.92%
13,276 $0
Q1 2018

May 14, 2018

BUY
$24.4 - $40.25 $18,446 - $30,429
756 Added 10.3%
8,099 $296,000
Q4 2017

Feb 13, 2018

BUY
$18.5 - $28.6 $135,845 - $210,009
7,343
7,343 $208,000

Others Institutions Holding AXGN

About Axogen, Inc.


  • Ticker AXGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 42,283,700
  • Market Cap $593M
  • Description
  • AxoGen, Inc., together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgic...
More about AXGN
Track This Portfolio

Track Principal Financial Group Inc Portfolio

Follow Principal Financial Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Principal Financial Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Principal Financial Group Inc with notifications on news.